FDA OKs new use for Roche's Tecentriq

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

The FDA approves the use of Roche's (OTCQX:RHHBY) TECENTRIQ (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progressed during or following platinum-based chemotherapy and have progressed on an appropriate FDA-approved targeted therapy if their tumor was EGFR- or ALK-positive.

Results from the Phase 3 OAK study showed NSCLC patients treated with atezolizumab lived a median of 4.2 months longer than those treated with docetaxel chemo with 27% less risk of death or cancer progression.

Atezolizumab is a PD-L1 antagonist that is designed to block inhibitory T-cell checkpoints thereby allowing cytotoxic T cells to reach the tumor. In May, the FDA approved it for the treatment of urothelial cancer.